Sulbactam·ampicillin in urinary tract infections

Daisuke Yamada; Yositsugu Nasu; Masaya Tsugawa; Mikio Kishi; Hiromi Kumon; Hiroyuki Ohmori; Katsuichi Nanba; Yasuhiro Katayama; Nobuyuki Akazawa; Toshihiko Asahi

doi:10.11250/chemotherapy1953.36.Supplement8_415

Sulbactam·ampicillin in urinary tract infections

Daisuke Yamada, Yositsugu Nasu, Masaya Tsugawa, Mikio Kishi, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yasuhiro Katayama, Nobuyuki Akazawa, Toshihiko Asahi

Research output: Contribution to journal › Article › peer-review

Abstract

We clinically investigated a new combination drug, sulbactam·ampicillin (SBT·ABPC) at the ratio 1:2, in the urological field. SBT·ABPC was administered to 24 patients with complicated urinary tract infections at a dose of 1.5 g twice daily for 5 days. The clinical efficacy rate was 75% according to the criteria of the Japanese UTI committee. Bacteriologically, 23 of 29 organisms (79%) were eradicated. There were no subjective side effects, but slight elevation of transaminase was noted in three cases.

Original language	English
Pages (from-to)	415-423
Number of pages	9
Journal	CHEMOTHERAPY
Volume	36
DOIs	https://doi.org/10.11250/chemotherapy1953.36.Supplement8_415
Publication status	Published - Jan 1 1988

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.36.Supplement8_415

Cite this

@article{10e4ee5b604e4411a398b3b4e5a3ecb6,

title = "Sulbactam·ampicillin in urinary tract infections",

abstract = "We clinically investigated a new combination drug, sulbactam·ampicillin (SBT·ABPC) at the ratio 1:2, in the urological field. SBT·ABPC was administered to 24 patients with complicated urinary tract infections at a dose of 1.5 g twice daily for 5 days. The clinical efficacy rate was 75% according to the criteria of the Japanese UTI committee. Bacteriologically, 23 of 29 organisms (79%) were eradicated. There were no subjective side effects, but slight elevation of transaminase was noted in three cases.",

author = "Daisuke Yamada and Yositsugu Nasu and Masaya Tsugawa and Mikio Kishi and Hiromi Kumon and Hiroyuki Ohmori and Katsuichi Nanba and Yasuhiro Katayama and Nobuyuki Akazawa and Toshihiko Asahi",

year = "1988",

month = jan,

day = "1",

doi = "10.11250/chemotherapy1953.36.Supplement8_415",

language = "English",

volume = "36",

pages = "415--423",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Sulbactam·ampicillin in urinary tract infections

AU - Yamada, Daisuke

AU - Nasu, Yositsugu

AU - Tsugawa, Masaya

AU - Kishi, Mikio

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuichi

AU - Katayama, Yasuhiro

AU - Akazawa, Nobuyuki

AU - Asahi, Toshihiko

PY - 1988/1/1

Y1 - 1988/1/1

N2 - We clinically investigated a new combination drug, sulbactam·ampicillin (SBT·ABPC) at the ratio 1:2, in the urological field. SBT·ABPC was administered to 24 patients with complicated urinary tract infections at a dose of 1.5 g twice daily for 5 days. The clinical efficacy rate was 75% according to the criteria of the Japanese UTI committee. Bacteriologically, 23 of 29 organisms (79%) were eradicated. There were no subjective side effects, but slight elevation of transaminase was noted in three cases.

AB - We clinically investigated a new combination drug, sulbactam·ampicillin (SBT·ABPC) at the ratio 1:2, in the urological field. SBT·ABPC was administered to 24 patients with complicated urinary tract infections at a dose of 1.5 g twice daily for 5 days. The clinical efficacy rate was 75% according to the criteria of the Japanese UTI committee. Bacteriologically, 23 of 29 organisms (79%) were eradicated. There were no subjective side effects, but slight elevation of transaminase was noted in three cases.

UR - http://www.scopus.com/inward/record.url?scp=0024230425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024230425&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.36.Supplement8_415

DO - 10.11250/chemotherapy1953.36.Supplement8_415

M3 - Article

AN - SCOPUS:0024230425

SN - 0009-3165

VL - 36

SP - 415

EP - 423

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Sulbactam·ampicillin in urinary tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this